KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Gross Profit Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+1223.8%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+1223.8%/yr
vs -63.0%/yr prior
Acceleration
+1286.8pp
Accelerating
Percentile
P100
Near historical high
vs 3Y Ago
2319.9x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 1390.43% |
| Q3 2025 | 105.26% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 100.00% |
| Q2 2024 | -12097.10% |
| Q1 2024 | 98.92% |
| Q4 2023 | 1.13% |
| Q3 2023 | 19.39% |
| Q2 2023 | -19.38% |
| Q1 2023 | -10.99% |
| Q4 2022 | 0.60% |
| Q3 2022 | 5.35% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |
| Q4 2021 | 0.00% |
| Q3 2021 | 100.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 100.00% |
| Q2 2020 | -458.97% |
| Q1 2020 | -59.77% |
| Q4 2019 | 16.36% |
| Q3 2019 | 15.14% |
| Q2 2019 | -24.78% |
| Q1 2019 | -30.44% |
| Q4 2018 | 50.40% |
| Q3 2018 | -23.18% |
| Q2 2018 | 107.64% |
| Q1 2018 | 106.83% |
| Q4 2017 | 1073.96% |
| Q3 2017 | -15.79% |
| Q2 2017 | -54.03% |
| Q1 2017 | 0.00% |
| Q3 2016 | -100.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | -12.50% |
| Q4 2015 | 14.29% |